Pathfinder Medical
Climate & Sustainability • East of England • Growth
Pathfinder Medical is developing a novel electronic guidance system that will enable clinicians to connect blood vessels in a minimally invasive way.
This platform technology can provide a safer, more reliable way for patients to receive haemodialysis or bypass arterial blockages. Worldwide, these unmet clinical needs represent a £4.2 billion yearly available market
Company
information
Investment date
Jan 2022
Head office
London
Chair
Chas Taylor
There are over three million dialysis patients worldwide and every year patients undergo nearly 650,000 surgical AVF creation procedures. However, these procedures take a long time to heal and are prone to failure. Our technology has the power to significantly improve the outcomes for dialysis patients, improving their quality of life and saving millions of pounds in the process. We are delighted to have the support of BGF and Parkwalk to help the business move forward with our clinical trials and ultimately roll-out this ground-breaking product to a global market.
Sorin Popa, CEO